Mealey's (February 8, 2018, 8:54 AM EST) -- ALEXANDRIA, Va. — A patented method for treating inflammatory autoimmune diseases with a high concentration subcutaneous methotrexate formulation was confirmed as patentable on Feb. 7 by the Patent Trial and Appeal Board (Koios Pharmaceuticals LLC v. medac Gesellschaft für klinische Spezialpräparate mbH, No. IPR2016-01370, PTAB)....